Key result
Avacopan faces critical scrutiny over its clinical viability due to emerging ADVOCATE trial controversies.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“There are two aspects to this issue, one is the efficacy, and the other is the liver toxicity. Foremost, our priority is to our patients. DILI has been seen more often in Asian patients, particularly in Japan, with eight Japanese patients of low body weight who were also taking co-trimoxazole reported to have developed VBDS so far.”
“CDER proposes to withdraw approval of Tavneos because of new information, which was withheld from FDA and did not become known to FDA until more than 3 years after approval, indicating that there is a lack of substantial evidence of effectiveness for the drug, and the application contains untrue statements of material facts.”
“Patient safety is our highest priority. Following a thorough review of the available evidence, we have concluded that the data supporting the efficacy of Avacopan Vifor is no longer sufficiently reliable to support a positive benefit-risk balance.”
Avacopan adoption warrants caution amid ADVOCATE controversies; leaves open its role in AAV pending independent verification.
‐
No takes yet. Share an insight, caveat, or question.
Chapman et al. (2026) studied this question. Avacopan faces critical scrutiny regarding its future clinical viability due to emerging controversies surrounding the pivotal ADVOCATE trial.
Synapse has enriched 10 related papers. Consider them for comparative context: